Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Book of Award

Prof. Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Guangzhou Medical University | China

Prof. Lingmin Zhang is a leading researcher whose work integrates pharmaceutics, biomedical materials, and gene delivery, contributing significantly to advanced therapeutic strategies, particularly in lung cancer and inflammatory diseases. With 3,077 citations , 79 publications, and an h-index of 27, the researcher's scholarly impact is widely recognized. The work focuses on innovative nano-based and biomimetic delivery platforms, including nano-PROTACs, exosomes, microfluidic nanovesicles, and CRISPR/Cas9 carriers, offering transformative possibilities for targeted and precision medicine. Supported by major grants from the National Natural Science Foundation of China (projects 82572415, 82072047, 81700382), the researcher has developed cutting-edge strategies such as reprogramming tumor-associated macrophages, overcoming drug resistance in lung cancer, and reversing epigenetic silencing through nanoparticle-mediated gene delivery. Influential publications in high-impact journals—including Journal of Controlled Release, Drug Resistance Updates, ACS Nano, Angewandte Chemie, Advanced Science, and Molecular Cancer—highlight breakthroughs in nano-therapeutics, PROTAC technologies, artificial exosomes, and nucleic-acid delivery systems. Collectively, these contributions position the researcher at the forefront of translational nanomedicine, with ongoing work offering new directions for precision oncology, regenerative strategies, and next-generation drug delivery platforms.

Profile : Scopus | Orcid

Featured Publication

He, M., Peng, Q., Yang, Q., Guan, X., Liu, Q., Chen, R., Zhou, D., Wang, L., Zhang, Y., Li, S., Su, J., & Zhang, L. (2026). In situ reprogramming of tumor associated macrophages with versatile nano-epigenetic inhibitor for lung cancer therapy. Journal of Controlled Release, 2026, 114497.

Zhang, L., He, L., Lin, Y., Wei, J., Tang, S., Lei, X., Lin, X., Zhou, D., Fu, L., Li, Y., He, J., Liang, L., & Yu, X. (2026). The novel strategy to overcome drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells. Drug Resistance Updates, 84, 101316.

Chen, S., Chen, E., Su, J., Gong, Y., Tang, S., Qin, A., Shen, A., Tang, S., & Zhang, L. (2025). Magnetically navigated nano-PROTAC ameliorates acute lung injury. Journal of Nanobiotechnology, 23, 622.

Li, X., Qin, Z., Wang, S., Zhang, L., & Jiang, X. (2025). Microfluidics-assembled nanovesicles for nucleic acid delivery. Accounts of Chemical Research, 58, 570–582.

Liang, L., Peng, W., Qin, A., Zhang, J., Chen, R., Zhou, D., Zhang, X., Zhou, N., Yu, X., & Zhang, L. (2024). Intracellularly synthesized artificial exosome treats acute lung injury. ACS Nano, 18(32), 21009–21023.

Guan, X., Xu, X., Tao, Y., Deng, X., He, L., Lin, Z., Chang, J., Huang, J., Zhou, D., Yu, X., Wei, M., & Zhang, L. (2024). Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy. Journal of Nanobiotechnology, 22, 692.

Zhang, L., Lin, Y., Li, S., Guan, X., & Jiang, X. (2023). In situ reprogramming of tumor-associated macrophages with internally and externally engineered exosomes. Angewandte Chemie International Edition, 62(11), e202217089.

Liang, L., Cen, H., Huang, J., Qin, A., Xu, W., Wang, S., Chen, Z., Tan, L., Zhang, Q., Yu, X., Yang, X., & Zhang, L. (2022). The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy. Molecular Cancer, 21(1), 186.

Zhang, H., Peng, R., Chen, S., Shen, A., Zhao, L., Tang, W., Wang, X., Li, Z., Zha, Z., Yi, M., & Zhang, L. (2022). Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy. Advanced Science, 9(29), 2202039.

Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019). Triple-targeting delivery of CRISPR/Cas9 to reduce the risk of cardiovascular diseases. Angewandte Chemie International Edition, 58(36), 12404–12408.

Jin-Lu Huang | Pharmacology, Toxicology and Pharmaceutical Science | Best Scholar Award

Published on by Book of Award

Dr. Jin-Lu Huang | Pharmacology, Toxicology and Pharmaceutical Science | Best Scholar Award

Shanghai Sixth People's Hospital | China

Author Profile

Scopus

🎓 Early Academic Pursuits

Dr. Jin-Lu Huang’s academic journey reflects a steadfast dedication to the pharmaceutical sciences. He began his higher education at Lin Yi University, earning a Bachelor’s Degree in Life Science in 2004. He then pursued a Master’s Degree in Microbiology and Biochemical Pharmacy at the China Pharmaceutical University, graduating in 2007. Driven by a passion for research, Dr. Huang completed his PhD in Pharmacy at Shanghai Jiao Tong University in 2012, laying the foundation for a research-intensive career in pharmacology and clinical applications.

💼 Professional Endeavors

Since July 2012, Dr. Huang has served as a Pharmacist at the Department of Pharmacy, Shanghai Sixth People’s Hospital, affiliated with Shanghai Jiao Tong University School of Medicine. His clinical expertise is complemented by an earlier role (2007–2008) as a Researcher at Shanghai Hengrui Pharmaceutical Co., Ltd., where he was involved in cutting-edge drug development and R&D processes.

🔬 Contributions and Research Focus

Dr. Huang's research spans ionomic metabolism, neuropathic and bone cancer pain, drug-induced side effects, and hospital pharmaceutical practices. His work often bridges basic pharmacological science with clinical application, focusing on pain modulation, calcium signaling pathways, and drug safety evaluation. He has authored over 20 peer-reviewed articles, including high-impact studies on analgesic mechanisms, store-operated calcium entry in neuropathy, and bone cancer pain ionomics. Notably, many of his papers explore pain at a molecular level, offering insights into sphingosine-1-phosphate receptors, ionomic profiles, and nuclear receptor signaling pathways.

🏅 Accolades and Recognition

Dr. Huang is a respected member of several leading professional societies including the Chinese Pharmacological Society, the International Union of Basic and Clinical Pharmacology, and the British Pharmacological Society. His extensive publication record, both as a lead author and co-investigator, reflects international recognition and collaboration. His research has appeared in journals like FEBS Open Bio, Pain, Scientific Reports, and Pharmaceutical Biology.

🌏 Impact and Influence

Dr. Huang's work has contributed significantly to the pharmacological understanding of chronic pain, particularly in the context of bone cancer and neuropathy. His analyses using bioinformatics tools like GoPubMed and his contributions to visualizing research trends have informed policy and practice in hospital pharmacy and drug safety evaluation. His studies are frequently referenced by fellow researchers and clinicians dealing with oncology-related pain and pharmaceutical practices in hospitals.

🔮 Legacy and Future Contributions

As a bridge between clinical pharmacy and laboratory research, Dr. Jin-Lu Huang is poised to leave a lasting legacy in translational pharmacology. With ongoing investigations into neuroinflammation, analgesic mechanisms, and metabolic responses to drug therapies, he continues to shape the future of personalized and precision medicine in pain management. His commitment to advancing both theoretical insights and clinical practices ensures that his contributions will benefit patients and healthcare systems for years to come.

 

Publications

  • 📄Involvement of ionomic metabolism of both the cerebrospinal fluid and the spinal cord in the analgesic efficacy of matrine in rats
    Authors: Huang JL, Tang CY, Fu Y, Wan LL, Li J, Sun XP, Hu JL, Zhang YY, Qu LY, Fu MJ, Zhang YY, Ma L, Guo C, Chen JG
    Journal: Pharmaceutical Biology
    Year: 2025
  • 📄Bckdk-Mediated Branch Chain Amino Acid Metabolism Reprogramming Contributes to Muscle Atrophy during Cancer Cachexia
    Authors: Chen L, Zhang H, Chi M, Guo C, Yang Q
    Journal: Molecular Nutrition and Food Research
    Year: 2024
  • 📄Astilbin exerts anti-hypersensitivity by regulating metabolic demand and neuronal activity in rodent model of neuropathic pain
    Authors: Wang Q, Duan D, Luo C, Yang S, Ma L
    Journal: Annals of Medicine
    Year: 2024
  • 📄Analysis of Ionomic Profiles of Spinal Cords in a Rat Model with Bone Cancer Pain
    Authors: Huang JL, Chen JG, Ma L, Zhu XY, Wan LL, Li XY, Guo C
    Journal: Journal of Pain Research
    Year: 2024
  • 📄Store-operated calcium entry mediates hyperalgesic responses during neuropathy
    Authors: Wang W, Wang Q, Huang JL, Li H, Li F, Li X, Liu R, Xu M, Chen J, Mao Y, Ma L
    Journal: FEBS Open Bio
    Year: 2023

 

Theopista Lotto | Health Professions | Best Research Article Award

Published on by Book of Award

Ms. Theopista Lotto | Health Professions | Best Research Article Award

Ifakara Health Institute | Tanzania

Author Profile

Orcid

🎓 Early Academic Pursuits

Ms. Theopista Lotto embarked on her academic journey with a deep commitment to healthcare and research. She earned her Bachelor of Pharmacy from Muhimbili University, Dar es Salaam, Tanzania (2003-2007), laying a strong foundation in pharmaceutical sciences. Her passion for healthcare monitoring and evaluation led her to pursue an MSc in Health Monitoring and Evaluation at Mzumbe University, Morogoro, Tanzania (2013-2015). Further advancing her expertise, she attained a PhD in Epidemiology and Public Health from Swiss TPH, Switzerland (2021-2023), equipping her with cutting-edge skills in public health research and antimicrobial resistance (AMR) studies.

💼 Professional Endeavors

Ms. Lotto has demonstrated exceptional leadership and expertise in public health, antimicrobial stewardship, and pharmaceutical research through her extensive professional journey. She currently serves as an M&E Advisor for the CDC Project on Sustainable Health System Strengthening at Mzumbe University (2024-Present), where she designs and implements evaluation frameworks and supports national health initiatives. Her role as a Technical Expert and In-Country Consultant for the Commonwealth Pharmacist Association (2023-Present) underscores her influence in antimicrobial stewardship, ensuring that healthcare programs align with Tanzania’s National Action Plan on AMR. Previously, she was a Research Scientist at Ifakara Health Institute (2020-2024), where she led multiple AMR surveillance projects and cross-sectional studies on antimicrobial use. Her earlier career includes impactful roles such as M&E Advisor at Tanzania Institute of Monitoring and Evaluation (2019-2020), DHIS2 Coordinator at Mbeya District Council (2015-2019), and District Pharmacist at Mbeya District Council (2009-2015). These positions highlight her extensive experience in data-driven decision-making, pharmaceutical logistics, and healthcare policy implementation.

🔬 Contributions and Research Focus

Ms. Lotto’s research focuses on antimicrobial resistance, antimicrobial stewardship, public health surveillance, and health system strengthening. She has played a pivotal role in:

  • Designing and leading AMU & AMS projects at Ifakara Health Institute, conducting large-scale community surveys to assess antimicrobial use in Tanzania.
  • Implementing electronic Clinical Decision Support Algorithms (CDSA) to promote antibiotic stewardship and improve pediatric healthcare outcomes.
  • Enhancing health monitoring systems through her expertise in Health Information Systems (DHIS2) and supporting national stakeholders with data-driven decision-making.

Her research has significantly contributed to the development of antimicrobial resistance policies, ensuring that Tanzania aligns with global AMR mitigation strategies.

🏆 Accolades and Recognition

Ms. Lotto’s contributions have earned her recognition as a leading researcher in public health and pharmacy. She has been instrumental in multiple government and international health projects, showcasing her ability to foster cross-sector collaborations with organizations like the CDC, Commonwealth Pharmacist Association, and Ifakara Health Institute. Her technical expertise in antimicrobial stewardship has positioned her as a sought-after consultant in Tanzania’s healthcare system.

🌍 Impact and Influence

Ms. Lotto’s work has had a far-reaching impact on Tanzania’s public health landscape. She has:

  • Strengthened AMR surveillance and antimicrobial stewardship programs at a national level.
  • Improved healthcare monitoring and evaluation frameworks through innovative data collection and analysis.
  • Supported policy formulation and implementation, working closely with government ministries and international health bodies.
  • Provided training and mentorship to healthcare professionals, ensuring sustainable knowledge transfer in pharmaceutical management and public health research.

Her influence extends beyond research; she actively engages policymakers, healthcare practitioners, and academic institutions to drive meaningful change in the fight against AMR.

🔮 Legacy and Future Contributions

As a visionary leader in public health and pharmacy, Ms. Lotto continues to pave the way for stronger healthcare systems in Tanzania. Her future contributions are expected to focus on:

  • Expanding AMR research to include more comprehensive national and regional studies.
  • Developing innovative pharmaceutical management tools to optimize drug distribution and usage.
  • Strengthening international collaborations to combat antimicrobial resistance on a global scale.
  • Training and mentoring the next generation of researchers in epidemiology and public health.

With her unwavering dedication and expertise, Ms. Lotto is set to leave a lasting legacy in global health research and pharmaceutical sciences, ensuring sustainable and evidence-based healthcare practices for generations to come.

 

Publications

📄 Population-Based Prevalence of Antibiotic Residuals in Low, Moderate and High Malaria Endemicity Areas in Tanzania
Author(s): Theopista Lotto, Joanna Gallay, Martin Zuakulu, Beatrice Ternon, Laurent Arthur Decosterd, Alexandra V. Kulinkina, Blaise Genton
Journal: Antibiotics
Year: 2025